AR100680A1 - Anticuerpos anti-dr5 y moléculas que comprenden dominios de unión de dr5 de los mismos - Google Patents

Anticuerpos anti-dr5 y moléculas que comprenden dominios de unión de dr5 de los mismos

Info

Publication number
AR100680A1
AR100680A1 ARP150101706A ARP150101706A AR100680A1 AR 100680 A1 AR100680 A1 AR 100680A1 AR P150101706 A ARP150101706 A AR P150101706A AR P150101706 A ARP150101706 A AR P150101706A AR 100680 A1 AR100680 A1 AR 100680A1
Authority
AR
Argentina
Prior art keywords
molecules
antibodies
binding
same
molecule
Prior art date
Application number
ARP150101706A
Other languages
English (en)
Original Assignee
Macrogenics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Macrogenics Inc filed Critical Macrogenics Inc
Publication of AR100680A1 publication Critical patent/AR100680A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente se dirige al mAb 1 y mAb 2 del anticuerpo anti-DR5, y a versiones humanizadas y quiméricas de tales anticuerpos. Adicionalmente a moléculas de unión de DR5 que comprenden fragmentos de tales moléculas, y a moléculas biespecíficas que incluyen diacuerpos, BiTEs, anticuerpos biespecíficos de protuberancias / agujeros, etc., que; comprenden: (i) tales fragmentos de unión de DR5 y (ii) un dominio capaz de unirse a un epítopo de una molécula presente sobre la superficie de una célula efectora. Reivindicación 31: La molécula de unión de DR-5 anti-humano de conformidad con cualquiera de las reivindicaciones 1 - 30, caracterizada porque la molécula se utiliza en el tratamiento de cáncer.
ARP150101706A 2015-01-26 2015-05-29 Anticuerpos anti-dr5 y moléculas que comprenden dominios de unión de dr5 de los mismos AR100680A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562107786P 2015-01-26 2015-01-26

Publications (1)

Publication Number Publication Date
AR100680A1 true AR100680A1 (es) 2016-10-26

Family

ID=56544107

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150101706A AR100680A1 (es) 2015-01-26 2015-05-29 Anticuerpos anti-dr5 y moléculas que comprenden dominios de unión de dr5 de los mismos

Country Status (3)

Country Link
AR (1) AR100680A1 (es)
TW (1) TW201627322A (es)
WO (1) WO2016122701A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201907299XA (en) 2017-02-08 2019-09-27 Dragonfly Therapeutics Inc Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
DK3582806T3 (da) 2017-02-20 2023-09-11 Dragonfly Therapeutics Inc Proteiner, der binder her2, nkg2d og cd16
US20200231700A1 (en) * 2017-02-20 2020-07-23 Dragonfly Therapeutics, Inc. Proteins binding gd2, nkg2d and cd16
WO2018217947A1 (en) * 2017-05-23 2018-11-29 Dragonfly Therapeutics, Inc. A protein binding nkg2d, cd16 and a tumor-associated antigen
US20200157174A1 (en) * 2017-05-23 2020-05-21 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and ror1 or ror2
JP2020522474A (ja) * 2017-05-23 2020-07-30 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｎｋｇ２ｄ、ｃｄ１６、および腫瘍関連抗原に結合するタンパク質
CA3073117A1 (en) * 2017-08-16 2019-02-21 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16, and hla-e
US10774139B2 (en) * 2017-11-10 2020-09-15 Ngm Biopharmaceuticals, Inc. ANGPTL8-binding agents and methods of use thereof
CN109836500A (zh) * 2017-11-25 2019-06-04 深圳宾德生物技术有限公司 一种靶向dr5的单链抗体、嵌合抗原受体t细胞及其制备方法和应用
CN109957024A (zh) * 2017-12-25 2019-07-02 深圳宾德生物技术有限公司 一种靶向dr5的单链抗体、嵌合抗原受体t细胞及其制备方法和应用
CN109957020A (zh) * 2017-12-25 2019-07-02 深圳宾德生物技术有限公司 一种靶向dr5的单链抗体、嵌合抗原受体t细胞及其制备方法和应用
WO2019127215A1 (en) * 2017-12-28 2019-07-04 Nanjing Legend Biotech Co., Ltd. Multispecific chimeric receptors comprising an nkg2d domain and methods of use thereof
EP3749347A4 (en) * 2018-02-08 2021-11-03 Dragonfly Therapeutics, Inc. CANCER POLYTHERAPY INVOLVING MULTI-SPECIFIC BINDING PROTEINS THAT ACTIVATE NATURAL KILLER CELLS
MX2020008336A (es) 2018-02-08 2020-09-21 Dragonfly Therapeutics Inc Dominios variables de anticuerpos que se dirigen al receptor nkg2d.
US20210238290A1 (en) * 2018-05-07 2021-08-05 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and p-cadherin
EP4139361A4 (en) * 2020-04-23 2024-05-15 Baylor College Medicine OVERCOMING THE TUMOR MICROENVIRONMENT FOR CELLULAR THERAPY BY TARGETING MYELOID-DERIVED SUPPRESSOR CELLS VIA A SPECIFIC TRAIL-R2 RECEPTOR
AR124414A1 (es) 2020-12-18 2023-03-22 Century Therapeutics Inc Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable
WO2024083021A1 (zh) * 2022-10-20 2024-04-25 北京三诺佳邑生物技术有限责任公司 特异性结合TRAIL或FasL的抗体组合以及双特异性抗体

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003135075A (ja) * 2001-11-05 2003-05-13 Research Association For Biotechnology 新規な全長ｃＤＮＡ
US8029783B2 (en) * 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
US20090297530A1 (en) * 2006-05-22 2009-12-03 Feng Wang-Johanning Herv-k antigens, antibodies, and methods
WO2012002723A2 (ko) * 2010-06-29 2012-01-05 성균관대학교산학협력단 투명 전도성막, 이의 제조 방법, 및 이를 이용한 투명전극 및 소자
EP2948475A2 (en) * 2013-01-23 2015-12-02 AbbVie Inc. Methods and compositions for modulating an immune response

Also Published As

Publication number Publication date
TW201627322A (zh) 2016-08-01
WO2016122701A1 (en) 2016-08-04

Similar Documents

Publication Publication Date Title
AR100680A1 (es) Anticuerpos anti-dr5 y moléculas que comprenden dominios de unión de dr5 de los mismos
CO2017012553A2 (es) Moléculas de unión a lag-3
CY1124634T1 (el) Μορια προσδεσης pd-1 και lag-3 και μεθοδοι χρησης αυτων
CL2021003535A1 (es) Anticuerpos anti-cd33 y métodos para utilizarlos. (divisional de solicitud 3095-2019)
CL2019001926A1 (es) Anticuerpos anti-tigit y fragmentos de unión a antígeno; composición farmacéutica que los comprende; polinenucleótido que codifica dicho anticuerpo; vector que los comprende, célula hospedera; método para producir dicho anticuerpo o fragmento de unión a antígeno del mismo; y uso en el tratamiento del cáncer. (divisional de solicitud 310-2017).
PE20191208A1 (es) Anticuerpos anti-cd73 y usos de los mismos
CO2019012210A2 (es) Anticuerpos anti-trem2 y métodos para utilizarlos
CY1124771T1 (el) Αντισωματα εναντι-σορτιλiνης και μεθοδοι χρησης αυτων
AR110676A1 (es) Tratamiento del cáncer utilizando receptores de antígenos quiméricos
PH12018501554A1 (en) Ror1 antibody compositions and related methods
PE20190970A1 (es) Anticuerpos anti-cd40 y sus usos
CO2018011195A2 (es) Composiciones que comprenden una coformulación de anticuerpos anti-pd-l1 y anti-ctla-4
PE20180950A1 (es) Anticuerpos biespecificos especificos para un receptor de tnf coestimulador
EA201690447A1 (ru) БИСПЕЦИФИЧЕСКИЕ МОНОВАЛЕНТНЫЕ ДИАТЕЛА, КОТОРЫЕ СПОСОБНЫ СВЯЗЫВАТЬСЯ С gpA33 И CD3, И ИХ ПРИМЕНЕНИЯ
MX2018008934A (es) Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso.
EA201791270A1 (ru) Модифицированные april-связывающие антитела
EA202092417A1 (ru) Химерные рецепторы к dll3 и способы их применения
PE20181054A1 (es) Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion
PE20190737A1 (es) Anticuerpos anti-cd27
BR112016000666A2 (pt) Constructos de ligação de antígeno cd3 e cd19 biespecíficos
EA201990894A1 (ru) Анти-pd-1/анти-her2 гетеродимерное биспецифическое антитело со структурой природного антитела и способ его получения
CL2017000912A1 (es) Anticuerpos que se unen a ccr6 y sus usos
EA202190183A1 (ru) Антитела к siglec-5 и способы их применения
CL2018001238A1 (es) Moléculas de unión específicas para asct2 y usos de las mismas
AR096445A1 (es) Anticuerpos que se unen específicamente a la subunidad b de la toxina shiga

Legal Events

Date Code Title Description
FB Suspension of granting procedure